First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer

Published:2017-06-22 Issue:25 Volume:376 Page:2415-2426
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Carbone David P.,Reck Martin,Paz-Ares Luis,Creelan Benjamin,Horn Leora,Steins Martin,Felip Enriqueta,van den Heuvel Michel M.,Ciuleanu Tudor-Eliade,Badin Firas,Ready Neal,Hiltermann T. Jeroen N.,Nair Suresh,Juergens Rosalyn,Peters Solange,Minenza Elisa,Wrangle John M.,Rodriguez-Abreu Delvys,Borghaei Hossein,Blumenschein George R.,Villaruz Liza C.,Havel Libor,Krejci Jana,Corral Jaime Jesus,Chang Han,Geese William J.,Bhagavatheeswaran Prabhu,Chen Allen C.,Socinski Mark A.

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1613493

Cited by 2103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intrapatient variation in PD-L1 expression and tumor mutational burden and the impact on outcomes to immune checkpoint inhibitor therapy in patients with non-small-cell lung cancer;Annals of Oncology;2024-10

2. Genomic and molecular alterations associated with primary resistance to immune checkpoint inhibitors;Cancer Immunology, Immunotherapy;2024-09-13

3. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

4. Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB);2024-09-11

5. Immunotherapy and Radiotherapy for Older Patients with Locally Advanced Non-Metastatic Non-Small-Cell Lung Cancer Who Are Not Candidates for or Decline Surgery and Chemotherapy: A Practical Proposal by the International Geriatric Radiotherapy Group;Cancers;2024-09-09